Glenmark Pharma gets USFDA approval for Clobetasol Propionate Foam

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux 1‐E Foam, 0.05%, of Mylan Pharmaceuticals Inc.

Olux 1-E Foam (Clobetasol Propionate Foam) is used to treat inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis. According to IQVIA sales data for the 12 month period ending July 2019, the Olux‐E Foam, 0.05 per cent market achieved annual sales of approximately US$11.1 million,

Glenmark’s current portfolio consists of 161 products authorized for distribution in the U.S. marketplace and 54 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Last month, Glenmark had received final approval from the USFDA for Pimecrolimus cream, used to treat skin conditions such as eczema.

Glenmark Pharmaceuticals is a research‐driven, global, integrated pharmaceutical organization. It has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

On Monday, the stock of Glenmark was down by 1.6 per cent and closed at Rs. 384.90. During the day, it made an intra-day high and low of Rs. 392.55 and Rs. 381.65 respectively.